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Efforts to improve access to cancer medicines should not overlook exorbitant pricesn 17 September 2015, the much anticipated
Senate report on the Availability of new, innovative“the US —
traditionally
the bastion of
medicine price
deregulation —
now recognisesOand specialist cancer drugs in Australia was
released.1 The inquiry preceding the report, which
was triggered by concerns about inadequate and
inequitable access to cancer medicines, had
attracted over 200 submissions from doctors,
patients, patient advocacy groups and government
decision makers.
The report addressed the health burden of cancer on
our society; the impact on patients of delayed access to
cancer medicines; and the challenges of assessing
cost-effectiveness, particularly for rare cancers. It also
focused on ways of improving Australia’s processes of
health technology assessment (HTA), by which we
determine whether medicines are safe, effective and
cost-effective.that high drug
prices are the
biggest barrier to
patient access”
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In Australia, HTAs for medicines are carried out in
two phases. First, a pharmaceutical company makes a
submission to the Therapeutic Goods Administration,
which assesses a medicine’s efﬁcacy and safety. If the
medicine is approved, an application can be made to
the Pharmaceutical Beneﬁts Advisory Committee
(PBAC) to have the medicine subsidised by the
Pharmaceutical Beneﬁts Scheme (PBS). The PBAC
assesses whether the medicine is cost-effective in
comparison with existing therapies. For targeted
therapies, approval may also be sought from the
Medical Services Advisory Committee for
“companion diagnostics” that determine whether
patients are likely to respond to the treatment. If
medicines are not subsidised by the PBS, patients and
their doctors have to ﬁnd other means to gain access
to them, which may include enrolling in clinical trials,
seeking treatment through public hospitals or
appealing to pharmaceutical companies for free or
subsidised access. If unsuccessful, patients are left
with the pressure of raising the money themselves or
having to forgo treatment.
Those advocating in the Senate report for reform
argued that patients are forced into these situations far
too often because Australia’s HTA processes are
antiquated, inﬂexible, unpredictable and inequitable —
particularly for those with rare cancers, young
people with cancer, and cancer patients located in rural
and remote regions.214 MJA 204 (6) j 4 April 2016Proposed solutions to these problems included:
 providing multiple HTA pathways;
 prioritising the resources of regulators and payers
so that the most important and complex medicine
applications are given the most attention;
 enabling better coordination between decision-
making bodies to speed up decisions;
 enabling better communication with pharmaceutical
companies to set expectations early and
thereby reduce failures;
 leveraging off decisions made by overseas regulators
with comparable evidence standards;
 taking greater account of indirect economic
beneﬁts and outcomes, such as improvements
in productivity; and
 having greater focus on outcomes important to
patients and doctors.
It was also suggested that because companies may not
be commercially motivated to seek approval for non-
commercially attractive uses of their products, it should
be made easier for physicians, patient advocates and
other stakeholders to make applications. To help
regulators and payers make timely decisions, often in the
midst of great uncertainty about real beneﬁts, harms and
costs, it was also proposed that there should be broader
use of “managed entry” schemes in Australia— that is,
schemes in which further evidence is generated after
approval by the regulator or payer.
Cost of new cancer drugs
While it is important for Australia to reﬁne its HTA
principles and processes, what was notably absent from
the Senate report was an in-depth consideration of why
newcancermedicines cost somuch, andwhat canbedone
about it. Many new cancer drugs cost more than $100 000
per treatment,2,3 and it has been shown that in the United
States the launch price of cancer medicines has increased
by 10% per annum over almost 20 years.4 These prices
mean that unsubsidised medicines are well out of the
reach of all but the wealthiest individuals, and they place
intense political pressure on governments to subsidise
medicines that would otherwise have been considered
too expensive or supported by insufﬁcient evidence.
The report’s overlooking of drug prices is signiﬁcant
because adjusting HTA processes to provide earlier
access tomore drugswithout reforming the waywe price
cancer drugs will mean an increasingly large proportion
Perspectivesof our health budget will be directed to medicines in
general, and cancer medicines in particular. This has the
potential to create enormous opportunity costs and
inequities elsewhere in the system.
In this regard, there are lessons to be learned from other
jurisdictions. In its submission, the Society of Hospital
Pharmacists of Australia poignantly notes that theUnited
Kingdom’s Cancer Drugs Fund, which was set up to
provide access to cancer drugs not approved by the
National Institute for Health and Care Excellence, has
inadvertently resulted in the UK paying more for cancer
drugs than most other European countries, and
ultimately resulted in 25 of the 84 previously listed cancer
medicines not being funded in 2015e16.
The pressure on governments is likely to get worse.
According to the Pharmaceutical Research and
Manufacturers of America, there are almost 800 drugs in
development for cancer, ofwhich 98 are for lung cancer, 87
for leukaemia, 78 for lymphoma, 73 for breast cancer, 56 for
skin cancer and 48 for ovarian cancer.5 A recent report by
the IMS Institute predicts that 225newmedicineswill enter
themarket over thenext 5years, and that cancer treatments
represent the highest proportion of these drugs.6 Of the
cancer medicines being developed, 91% will be targeted
therapies, which is likely to make these medicines more
expensive. Pressure onbudgetswill thereforeonly increase
if something is not done now about cancer drug prices.
Perhaps one reason the Senate report focused somuch on
HTA, and not on drug prices, is that price and proﬁt
expectations for pharmaceutical markets are set
internationally, and Australia is a small player in this
market. Part of the pharmaceutical industry’s global
strategy includes setting high pricing precedents,
typically in the US market. Although companies do
negotiate different prices elsewhere in theworld, there is a
limit to their willingness to do so.
It is interesting, however, to observe that the US—
traditionally the bastion of medicine price deregulation—
nowrecognises that highdrugprices are thebiggestbarrier
to patient access, and questions are beginning to emerge
about the legitimacyof theprices being charged.AnewBill
has recently been submitted to the US Congress seeking to
empower the nation’s Medicare system (which provides
public health care primarily to people aged 65 years and
older) to drive down prices, and to demand reports about
expenditure and proﬁts for each drug listed with the US
Food and Drug Administration, including overseas sales.7
No doubt, recent scandals relating to unjustiﬁable price
hikes—most notably themore than 5000% increase for 60-
year-old drug pyrimethamine (Daraprim), used to treat
infections such asmalaria8— has contributed to the recent
spike in unease about medicine pricing.
A few submissions to the Senate report didmakemention
of the need for new approaches to purchasing medicines.
Rare Cancers Australia, for example, recommended
treating medicines as a service, wherein licences to use
medicines, rather than the medicines themselves, arebought and sold. The advantage of this approach is that
regardless of how much of a medicine is used, the
licensing fee remains ﬁxed, removing any incentive to
overprescribe or aggressively promote use of a medicine.
If such licences are not linked to speciﬁc indications, this
model may also provide subsidised access to off-label
drugs to treat patients with rare cancers.
Social impact bonds are another possible approach that
was recommendedby theCancerDrugsAlliance.A social
impact bond is a means to attract non-government
investment into projects that resolve social problems that
have traditionally relied on relatively small-scale support
from trusts and foundations. The premise is that dealing
with acute social problems early (eg, severe suffering
from cancer) will lead to less expensive interventions and
therefore savings for governments, of which a proportion
is provided to investors as reward.9
Where to from here?
Such dramatic changes to howwe procuremedicines will
need to be considered carefully and adopted gradually,
andperhaps all Australia can do for now iswait for global
drug pricing trends to adjust. Meanwhile, we need to be
cautious about demands to radically overhaul HTA
processes that might actually be working quite well. For
example, when it comes to managed entry programs, it
has to be recognised that current evidence standards
have evolved for a reason, and it is extremely difﬁcult
to disinvest if a medicine subsequently proves to be
ineffective, unsafe, poor value for money or simply
unaffordable. It is therefore crucial for decisionmakers to
separate the real value of cancer medicines from the hype
that often surrounds them— using, for example, a tool
developed by the European Society forMedicalOncology
that ranks the “clinically meaningful beneﬁt” that can be
expected from new cancer treatments.10
One change thatwe can safelymake now is to advocate for
greater transparency surrounding both HTA and price
negotiations. At present, decisions about access to
cancer medicines are made behind closed doors, largely
because of the perceived need to maintain commercial
conﬁdentiality. It is understandable that companieswould
not want to completely reveal their commercial interests,
but without greater openness about how funding
decisions aremade, and howmedicine prices are linked to
underlying research and development, manufacturing
and operational costs, we will remain unable to optimise
the utilisation of our health resources in a way that works
for both society and the pharmaceutical industry.
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